Intradermal Injection of 100mg Tranexamic Acid Versus Topical 4% Hydroquinone for the Treatment of Melasma: A Randomized, Controlled Trial.
Melasma
dermatology
hydroquinone
skincare
tranexamic acid
Journal
The Journal of clinical and aesthetic dermatology
ISSN: 1941-2789
Titre abrégé: J Clin Aesthet Dermatol
Pays: United States
ID NLM: 101518173
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
entrez:
6
2
2023
pubmed:
7
2
2023
medline:
7
2
2023
Statut:
ppublish
Résumé
Melasma is an acquired and chronic hyperpigmentation disorder associated with a negative impact on patients' quality of life. This study compares the efficacy of 100mg/mL intradermal TA with 4% topical HQ on female patients presenting with melasma lesions. In this randomized double-blind controlled trial, 48 women with melasma were allocated into two groups, treated with either 100mg/mL intradermal TA or topical 4% HQ. The MASI (Melasma Area and Severity Index) score was assessed by paired t-tests and repeated measured ANOVAs. The Dynamic Physician General Assessment (PGA) was also performed by taking photographs with a digital camera. The average MASI score for the HQ and TA groups was 7.7 (3.0 SD) and 5.9 (2.5 SD), respectively. In both groups, the MASI decreased significantly after three months of treatment; however, the decrease was not significant between the two groups ( First, we only used the MASI score to measure melasma degree. Second, this is a single-center study with a small sample size. Third, the before-after photos were not taken with a high-quality camera. The results of our study showed that both TA and continuous HQ significantly reduced the MASI score of patients without any significant differences and serious side effects. Although many treatment modalities are available for melasma, this condition is still challenging for dermatologists with a high recurrence rate after treatment.
Types de publication
Journal Article
Langues
eng
Pagination
35-40Informations de copyright
Copyright © 2023. Matrix Medical Communications. All rights reserved.
Déclaration de conflit d'intérêts
DISCLOSURES: The authors report no conflicts of interest relevant to the content of this article.
Références
J Eur Acad Dermatol Venereol. 2020 Apr;34(4):897-903
pubmed: 31858658
Dermatol Surg. 2006 May;32(5):626-31
pubmed: 16706756
Dermatol Ther. 2007 Sep-Oct;20(5):308-13
pubmed: 18045355
Indian J Dermatol Venereol Leprol. 2019 Jan-Feb;85(1):39-43
pubmed: 30333359
Clin Cosmet Investig Dermatol. 2019 Feb 14;12:115-122
pubmed: 30858717
BMC Dermatol. 2020 Aug 3;20(1):4
pubmed: 32746823
J Cosmet Dermatol. 2013 Mar;12(1):57-66
pubmed: 23438143
J Cosmet Laser Ther. 2011 Dec;13(6):265-79
pubmed: 21981383
An Bras Dermatol. 2015 Mar-Apr;90(2):196-200
pubmed: 25830989
J Cosmet Dermatol. 2015 Sep;14(3):174-7
pubmed: 26177992
Pak J Med Sci. 2020 Jul-Aug;36(5):930-934
pubmed: 32704266
Indian J Dermatol. 2009;54(4):303-9
pubmed: 20101327
J Dermatolog Treat. 2018 Jun;29(4):405-410
pubmed: 29027510
Indian J Dermatol. 2009;54(1):92-3
pubmed: 20049286
J Cosmet Dermatol. 2017 Jun;16(2):235-242
pubmed: 27762489
J Cosmet Dermatol. 2021 Nov;20(11):3593-3602
pubmed: 34591360
Clin Exp Dermatol. 2017 Oct;42(7):728-734
pubmed: 28649780
J Drugs Dermatol. 2020 Feb 01;19(2):184-187
pubmed: 32129968
Dermatitis. 2014 Jan-Feb;25(1):e1-5
pubmed: 24407054
Health Sci Rep. 2022 Mar 09;5(2):e537
pubmed: 35284654
J Dermatolog Treat. 2022 Jun;33(4):1816-1837
pubmed: 33849384
J Photochem Photobiol B. 1998 Dec;47(2-3):136-41
pubmed: 10093913
Dermatol Ther (Heidelb). 2017 Sep;7(3):305-318
pubmed: 28726212
Clin Exp Dermatol. 2008 May;33(3):305-8
pubmed: 18419607
Dermatol Res Pract. 2011;2011:379173
pubmed: 21822427
Int J Womens Dermatol. 2017 Dec 08;4(1):38-42
pubmed: 29872675
Int J Dermatol. 2006 Mar;45(3):285-8
pubmed: 16533230